Patents Assigned to Nanjing Sinogen Biotech & Pharmaceutical Inc.
  • Patent number: 10113184
    Abstract: It discloses a transformant for weight loss and lipid reduction, which is obtained by recombining and substituting human oxyntomodulin gene into thymidylate synthase gene of L.lactis genome. Wherein the recombinant substitution is homologous recombination by artificially synthesizing gene sequences, making the sequence flanking the human oxyntomodulin gene derived from the homologous sequences of thymidylate synthase gene in the L.lactis genome, then the gene fragments are electroporated into L. lactis, to carry out homologous recombination.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 30, 2018
    Assignee: NANJING SINOGEN BIOTECH & PHARMACEUTICAL INC.
    Inventors: Yan Lin, Rong Xiang, Allan Zijian Zhao, Fanghong Li
  • Patent number: 9816083
    Abstract: The current invention discloses a genetically engineered bacterium used for the treatment of breast cancer. The said bacterium is attenuated Salmonella typhimurium VNP20009 with cloned L-methioninase gene. The method for constructing this genetically engineered bacterium and the application thereof are also disclosed herein. In the current invention, our biologic drug for the treatment of breast cancer is a type of safe, non-toxic new drug with anti-tumor activity. It can highly express methioninase through recombinant DNA technology using attenuated Salmonella typhimurium VNP20009 as a carrier, which has a strong anti-tumor activity and can meet the needs. The preparation method is simple and easy to operate, showing good application prospect.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: November 14, 2017
    Assignee: NANJING SINOGEN BIOTECH & PHARMACEUTICAL INC.
    Inventors: Yan Lin, Sujin Zhou, Allan Zhao, Xiaoxi Li, Pengli Yu, Fanghong Li
  • Patent number: 9439934
    Abstract: The current invention discloses an attenuated Salmonella typhimurium, a genetically engineered bacterium and applications thereof in preparing drugs for the treatment of prostate cancer. The attenuated Salmonella typhimurium has tumor targeting and significant inhibitory effects on prostate cancer cells. A genetically engineered bacterium bearing a L-methioninase gene plasmid also has tumor targeting ability. The attenuated Salmonella typhimurium with the plasmid can constitutively express L-methioninase in the tumor tissues, consume a significant amount of methionine and other nutrients, which in turn causes lack of nutrition and slow growth of tumor cells. Therefore, it can be used as drugs for treating prostate cancer.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 13, 2016
    Assignee: NANJING SINOGEN BIOTECH & PHARMACEUTICAL INC.
    Inventors: Allan Zijian Zhao, Sujin Zhou, Yan Lin, Zhenggang Zhao, Fanghong Li
  • Publication number: 20150376593
    Abstract: The current invention discloses a genetically engineered bacterium used for the treatment of breast cancer. The said bacterium is attenuated Salmonella typhimurium VNP20009 with cloned L-methioninase gene. The method for constructing this genetically engineered bacterium and the application thereof are also disclosed herein. In the current invention, our biologic drug for the treatment of breast cancer is a type of safe, non-toxic new drug with anti-tumor activity. It can highly express methioninase through recombinant DNA technology using attenuated Salmonella typhimurium VNP20009 as a carrier, which has a strong anti-tumor activity and can meet the needs. The preparation method is simple and easy to operate, showing good application prospect.
    Type: Application
    Filed: February 27, 2014
    Publication date: December 31, 2015
    Applicant: Nanjing Sinogen Biotech & Pharmaceutical Inc.
    Inventors: Yan Lin, Sujin Zhou, Allan Zhao, Xiaoxi Li, Pengli Yu, Fanghong Li